You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

Version: 5 ID: GL 8-1 Aug 2019
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Teresa M. Petrella, Tara D. Baetz, Glenn G. Fletcher, Gregory Knight, Elaine McWhirter, Sudha Rajagopal, Xinni Song, and members of the Melanoma Disease Site Group

Guideline Objective

To make recommendations regarding the use of adjuvant systemic therapy in adult patients with completely resected cutaneous or mucosal melanoma with a high risk of recurrence. 

Patient Population

Adult patients with cutaneous or mucosal melanoma with high risk of recurrence who are rendered disease-free following resection (including resection of all locoregional or distant metastases, if present). Patients with unresected primary disease or metastases fall outside the scope of this document.

Intended Guideline Users

Medical oncologists, surgical oncologists, and other health care providers involved in the management and referral of patients with resected melanoma at high risk for recurrence.

Research Question(s)

  1. What systemic therapy should clinicians recommend to adult patients who have been rendered disease-free following the resection of cutaneous melanomas (including all sites of metastases, if present) and who are at high risk for subsequent recurrence?
  2. What systemic therapy should clinicians recommend to adult patients who have been rendered disease-free following the resection of mucosal melanomas?
pdf download Summary (PDF) (260.8 KB)